DF-003 is under clinical development by Drug Farm and currently in Phase I for Unspecified Ophthalmological Disorders.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

A Wolters Kluwer Health prediction report features 25 wide-ranging predictions spanning health AI, preventing burnout, tech ...

Proteolytic targeting chimera (PROTAC) is a new type of drug design technology that works by inducing the degradation of target proteins. Unlike conventional small molecules that typically inhibit ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

A team led by researchers at the University of Toronto has created a platform, called SIMPL2, that improves the study of ...

Designed to detect drugs of abuse through sweat collected from the fingertips and provide results within ten minutes, the non ...

The Macao IP Office has assigned number J/9010 to the patent with an entry date of December 17, 2024. Macao is a Special Administrative Region (SAR) of the People’s Republic of China which affords it ...